find the latest legal job
Senior Associate - Litigation & Dispute Resolution
Category: Litigation and Dispute Resolution | Location: Melbourne CBD & Inner Suburbs Melbourne VIC
· Come work for a firm ranked in Lawyers Weekly Top 25 Attraction Firms
View details
Associate - Workplace Relations & Safety
Category: Industrial Relations and Employment Law | Location: Brisbane CBD & Inner Suburbs Brisbane QLD
· Employer of choice · Strong team culture
View details
Freelance Lawyers
Category: Banking and Finance Law | Location: All Perth WA
· Freelance opportunities through Vario from Pinsent Masons
View details
Freelance Lawyers
Category: Other | Location: All Adelaide SA
· • Qualified lawyer with a strong academic background
View details
Freelance Lawyers
Category: Other | Location: All Melbourne VIC
· • Qualified lawyer with a strong academic background
View details
IP pendulum swings in favour of moderation

IP pendulum swings in favour of moderation

Naomi Pearce

A recent ruling by the Federal Court of Australia may encourage biopharma companies to take a more moderate approach to interlocutory relief, writes Naomi Pearce.

The much-anticipated Court of Appeal decision in Commonwealth of Australia v Sanofi was handed down on Monday. The decision is a win for the Commonwealth, and for generic/biosimilar companies in Australia, and (if upheld in any appeal) will result in sponsors adopting a more circumspect approach to seeking interlocutory injunctions for patent infringement in Australia.

Except where a generic/biosimilar applicant has “cleared the way” (cleared any patent impediments to launch through the courts in Australia) or all relevant patents have expired, interlocutory injunctions are routinely sought by the sponsor, and are routinely granted.

In order to get an interlocutory injunction in Australia, the applicant (here the sponsor) will generally be required to provide an undertaking as to damages. In the “usual undertaking as to damages”, the sponsor undertakes to submit to orders the court deems fit to compensate any person adversely affected by the interlocutory order in the event that it is ultimately overturned.

Until now, the risk of the Commonwealth seeking compensation for losses resulting from a prolonged PBS price premium (whilst the generic/biosimilar medicine is kept off the market because of the injunction) has been theoretical. Now it is very real.

The decision has confirmed that the Commonwealth may seek relief under the “usual undertaking as to damages”. After a detailed analysis of the certification requirements and related remedies of the Therapeutic Goods Act, the Court of Appeal confirmed that those provisions do not limit the ability of the Commonwealth to claim under the usual undertaking.

The impact of this decision is significant, if upheld in any appeal to the High Court. Leaving aside any compensation payable to the generic/biosimilar company for delayed market entry, the amount claimed against Sanofi by the Commonwealth is $54.8 million for the foregone/delayed 12.5 per cent PBS price reduction.

The pendulum may have started to swing back toward a moderate position regarding interlocutory relief in Australia. Product sponsors will have good reason to pause before seeking interlocutory relief on vulnerable patents in Australia; generic/biosimilar manufacturers may be afforded greater opportunities to launch “at risk”, without interlocutory prohibitions; and the Commonwealth (and the public) will be compensated for delays to competition due to interlocutory injunctions, which are ultimately overturned.

Naomi Pearce is a partner at K&L Gates

Like this story? Read more:

QLS condemns actions of disgraced lawyer as ‘stain on the profession’

NSW proposes big justice reforms to target risk of reoffending

The legal budget breakdown 2017

IP pendulum swings in favour of moderation
lawyersweekly logo
Promoted content
Recommended by Spike Native Network
more from lawyers weekly
Scales of Justice, ALA, right-to-die law
Oct 24 2017
‘Right-to-die’ laws would be a relief for terminally ill: ALA
The passage of an assisted dying bill through the lower house of Victorian Parliament has been haile...
Oct 24 2017
Diversity top of agenda for future WA Law Society president
The advancement of diversity in the Western Australian legal profession will be one of the key items...
Oct 23 2017
How to fail well
The legal profession is due for an attitude adjustment when it comes to perceived failures, accordin...
Allens managing partner Richard Spurio, image courtesy Allens' website
Jun 21 2017
Promo season at Allens
A group of lawyers at Allens have received promotions across its PNG and Australian offices. ...
May 11 2017
Partner exits for in-house role
A Victorian lawyer has left the partnership of a national firm to start a new gig with state governm...
Esteban Gomez
May 11 2017
National firm recruits ‘major asset’
A national law firm has announced it has appointed a new corporate partner who brings over 15 years'...
Nicole Rich
May 16 2017
Access to justice for young transgender Australians
Reform is looming for the process that young transgender Australians and their families must current...
Geoff Roberson
May 11 2017
The lighter side of the law: when law and comedy collide
On the face of it, there doesn’t seem to be much that is amusing about the law, writes Geoff Rober...
May 10 2017
Advocate’s immunity – without fear or without favour but not both
On 29 March 2017, the High Court handed down its decision in David Kendirjian v Eugene Lepore & ...